Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
Healthcare
$8.72 +5.01%
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
52W Low $7.21High $37.90
Volume 0.33M
Average 0.12M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$20.45M
FY 2025 · Annual
Investing Cash Flow
$19.77M
FY 2025 · Annual
-11.9% YoYFinancing Cash Flow
-$645,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.79M) | (48.59M) | (34.1M) | (30.16M) | (21.09M) |
| Depreciation & Amortization | 685K | 1.35M | 1.35M | 1.32M | 139K |
| Deferred Income Tax | 19K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.66M | 5.81M | 4.45M | 3.14M | 1.27M |
| Change in Working Capital | 117K | 1.01M | (4.33M) | (489K) | (1.59M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.43M) | 2.02M | (2.33M) | (445K) | 233K |
| Other Working Capital | 1.54M | (1.01M) | (2M) | (44K) | (1.83M) |
| Other Non-Cash Items | 57K | 1.4M | 603K | 1.52M | 811K |
| Operating Cash Flow | (30.26M) | (39.03M) | (32.02M) | (24.67M) | (20.45M) |
| Capital Expenditures | (2.03M) | (321K) | (180K) | (146K) | (16K) |
| Acquisitions (Net) | 318K | 15K | 166K | 0 | 250K |
| Purchases of Investments | (183.67M) | (46.87M) | (21.15M) | (44.6M) | (25.16M) |
| Sales of Investments | 42.26M | 97.12M | 59.58M | 67.18M | 44.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (143.12M) | 49.95M | 38.41M | 22.44M | 19.77M |
| Debt Repayment | (255K) | (629K) | (761K) | (811K) | (648K) |
| Common Stock Issued | 140.59M | 342K | 48K | 34K | 7K |
| Common Stock Repurchased | 0 | 0 | (10.38M) | 0 | (1K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 109K | 0 | (76K) | (10K) | (3K) |
| Financing Cash Flow | 163.94M | (287K) | (11.17M) | (787K) | (645K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.44M) | 10.64M | (4.78M) | (3.02M) | (1.33M) |
| Free Cash Flow | (32.29M) | (39.35M) | (32.2M) | (24.82M) | (20.47M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$21.1M
+ D&A$139.0K
+ Stock-Based Comp$1.3M
+ Deferred Tax$0
- Working Capital-$1.6M
+ Other Non-Cash$811.0K
= Operating Cash Flow-$20.5M
- Capex-$16.0K
= Free Cash Flow-$20.5M
Analysis
FY2025 free cash flow is -$20.5M. FCF conversion is 97.1% of net income. Operating cash flow was -$20.5M, with capex of -$16.0K. The largest bridge item is Working Capital at -$1.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| S-8 | S-8 filing | Nov 3, 2026 |
Does FTH generate free cash flow?
Faeth Therapeutics, Inc. (FTH) generated -$20.47M of free cash flow in fiscal 2025.
How much operating cash flow does FTH produce?
Operating cash flow was -$20.45M, before capital expenditures of $16,000.00.
Continue the stock analysis
Jump to another research area for this company.